都市激情在线亚洲国产91_欧美日韩国产国语对白_av成人毛片在线免费观看_少妇爆乳无码专区网站_亚洲Aⅴ无码吞精久久AV_亚洲AV毛片一区无码日韩_国产成人精品1024视频网站_最新综艺节目国产精品喷浆_国产在线拍揄自揄视频网站_天天少妇被猛烈进入在线播放

The Chinese Institutional Investor Conference and the 14th Golden Cicada Award Ceremony sponsored by China Times were held in Beijing on March 27, 2021. In this event, Kexing Biopharm (stock code: 688136) was awarded as the "2020 Top Listed Companies with Biggest Brand Value".

Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of therapeutic recombinant proteins, modified proteins, fusion proteins and micro-ecological drug products. It focuses on pharmaceutical research in the fields of antiviral, oncology and immunology, hematology, and digestive system. It is devoted to providing patients with better therapeutic drugs and solutions and creating more possibilities for the health of patients.

With over two decades of experience in pharmaceutical research and commercial production technology since the establishment, Kexing Biopharm has had 3 major technology systems (prokaryotic cell technology, eukaryotic cell technology and viable micro-ecological bacteria technology), and has set up 5 world-leading platforms for strain technology, recombinant protein pharmaceutical industrialization technology, micro-ecological drug product R&D and industrialization technology, recombinant protein secretion and expression technology, and long-acting recombinant protein technology. It has four core products including recombinant protein drugs "Human Erythropoietin", "Human Interferon α1b" and "Human Granulocyte Colony-stimulating Factor", and micro-ecological drug products "Combined Clostridium Butyricum and Bifidobacterium". All of those are first-line clinical drugs and steadily rank among the similar varieties in China. Those products have been adopted by more than 16,000 sales terminals, including more than 6,000 hospitals, in the provinces, municipalities and regions across China, and have been registered in and exported to more than 30 countries and regions such as Brazil, the Philippines and Indonesia.

In recent years, Kexing Biopharm has focused on biopharmaceuticals and geared to international conventions. The brand LOGO in a traditional style of pharmaceutical companies has been replaced by an eye-catching one. The new LOGO is a gecko with a regenerated tail to carry the meaning of self-healing ability, conforming to the attribute of Kexing Biopharm focusing on biomedicine. The LOGO is in bright color instead of dull color traditionally used in the pharmaceutical industry and thus it appears to be more attractive and highly distinctive. Kexing Biopharm is the only Chinese pharmaceutical company to win the Excellence Award of 2020 "REBRAND 100" for its brand visual design.

In addition to the visual upgrades of the brand, Kexing Biopharm relies on enterprise strategies and adheres to the philosophy of "Precise Products, Predictable Effects and Health Protection". Driven by "technological innovation", it insists on innovation in " doctor-patient insight, system agility, in-depth exploration and people-oriented innovation", and keeps exploring and improving its comprehensive strength.

With this award, Kexing Biopharm will bear the original aspiration of extreme excellence and innovation, uphold the mission of "Precise Products, Predictable Effects and Health Protection", focus on the development strategy of biopharmaceuticals, and provide patients with biotechnology, becoming the leader of high quality biologicals .